Benchmarking of laboratory evolved unspecific peroxygenases for the synthesis of human drug metabolites
P. Gomez de Santos (Institute of Catalysis, CSIC, Madrid)
Fadia V. Cervantes (Institute of Catalysis, CSIC, Madrid)
F. Tieves (TU Delft - BT/Biocatalysis)
Francisco J. Plou (C/, Institute of Catalysis, CSIC, Madrid)
F. Hollmann (TU Delft - BT/Biocatalysis)
Miguel Alcalde (Institute of Catalysis, CSIC, Madrid, C/)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
By mimicking the role of human liver P450 monooxygenases, fungal unspecific peroxygenases (UPOs) can perform a range of highly selective oxyfunctionalization reactions on pharmacological compounds, including O-dealkylations and hydroxylations, thereby simulating drug metabolism. Here we have benchmarked human drug metabolite (HDM) synthesis by several evolved UPO mutants, focusing on dextromethorphan, naproxen and tolbutamide. The HDM from dextromethorphan was prepared at the semi-preparative scale as a proof of production. The structural analysis of mutations involved in the synthesis of HDMs highlights the heme access channel as the main feature on which to focus when designing evolved UPOs. These variants are becoming emergent tools for the cost-effective synthesis of HDMs from next-generation drugs.